The project is the result of a partnership in which the pharmaceutical industries of China and Europe collaborate
When pharmaceutical excellence collaborates, success is guaranteed. One of the latest projects comes from a partnership in which pharmaceutical companies from China and Europe collaborate and to create a vaccine that can prevent infection with up to 20 types of viruses, including what can lead to cervical cancer.
In particular, Xiamen Innovax Biotech Co Ltd, a Yang Sheng-Tang group from Hangzhou, signed a global alliance agreement last month with the British pharmaceutical giant GlaxoSmithKline (GSK) to develop a new-generation vaccine against human papillomavirus (HPV).
It should be noted that this was the first time that a Chinese vaccine company has partnered with a world-leading pharmaceutical conglomerate to jointly develop and market a new vaccine. At the moment, in fact, most of the HPV vaccine products available in the world only protect against a maximum of nine types of viruses.
The vaccine will use an innovative method of antigen detection.
Zhong Shanshan, chairman of the YangShengTang Group, said: “Such an alliance shows that the country’s core technology in research and development in the field of vaccines has reached an unprecedented level and the partnership is an exemplary winwin collaboration between industries pharmaceuticals from China and Europe “.
“It is also the first time that Chinese vaccine technology has seized the opportunity to walk to the center of the world stage and play a role in the battlefield of global vaccines,” said Zhang Rong, president of Xiamen University .
GSK said the collaboration with Innovax will accelerate the development of a new generation vaccine for cervical cancer, the third most common cancer in women.
The world’s first hepatitis E vaccine was approved in China in 2012
Under the agreement, Innovax will build a vaccine production line in Xiamen that meets the standards of China, the United States, the European Union and the World Health Organization. In addition, it will produce and supply GSK with various types of HPV vaccine antigens, which will be combined with GSK’s patented adjuvant to develop new HPV vaccines for worldwide marketing.
Zhong, who is also president of Innovax, added: “International pharmaceutical giants usually buy research and development results early on, but they take control of the basic development and production procedures in the secondary phase alone. But in this case, Innovax won the production of vaccine antigens after adequate GSK research and evaluation “.
The key competitiveness of the Xia team lies in developing a technique that protects against three types of HPV with a single virus-like particle. The research was published in Nature Communications, based in the United Kingdom, in December.
“The current one-to-one technique limits the development of high-value vaccines as a vaccine product that protects from more than 10 types of viruses means a high dosage, the possibility of more potential side effects and a greater complexity and cost of production of the vaccine “he said.
MORE ON THIS TOPIC